Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Afatinib 40 MG Oral Tablet [Gilotrif]

Known as: Gilotrif 40 MG (as afatinib dimaleate 59.12 MG) Oral Tablet, Gilotrif 40 MG Oral Tablet, afatinib 40 mg ORAL TABLET, FILM COATED [Gilotrif] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that have common epidermal growth factor… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2018
2018
  • E. Deeks, G. Keating
  • Drugs & therapy perspectives : for rational drug…
  • 2018
  • Corpus ID: 3959001
Afatinib [Giotrif® (EU); Gilotrif® (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
Afatinib (Gilotrif™) is widely used to treat patients with mutant activating epidermal growth factor receptor- (EGFR-) dependent… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2016
2016
Background: miRNAs play a critical role in regulating key biological processes by modulating the expression of up to several… Expand
Is this relevant?
Review
2016
Review
2016
  • G. Keating
  • Targeted Oncology
  • 2016
  • Corpus ID: 35318980
Afatinib (Giotrif®, Gilotrif®) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. In the… Expand
  • table 1
  • table 2
Is this relevant?
2016
2016
Background: The differentiation of tablets by their physical appearance is a contributing factor to the safe use of medications… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2013
Review
2013
Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. Afatinib… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2013
Review
2013
Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for… Expand
Is this relevant?